Mesoblast Q4 2022 Operational Highlights & Financial Results

Mesoblast is a global leader in allogeneic cellular medicines for inflammatory diseases. The company presented operational highlights and financial results for the quarter ended December 31, 2022, detailing progress in adult stem cell technologies and regulatory advancement.